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Abstract
Purpose: To determine the efficacy and safety of infliximab therapy in patients
with HLA B-27-associated ocular inflammation resistant or intolerant to conventional
immunomodulatory therapy.
Methods: This was a retrospective observational case series. All cases were uveitic
patients with positive HLA-B27, confirmed through HLA testing, resistant or intolerant
to conventional immunomodulatory therapy. The primary outcome of the study was to
identify the efficacy of infliximab determined by the control of inflammation, duration
of remission, and the ability to reduce conventional immunomodulatory therapy. The
secondary outcome was an improvement of two or more lines of best-corrected visual
acuity (BCVA) on the Snellen visual acuity chart.
Results: Twenty-four patients (38 eyes) were included in the study. All patients were
followed for 24 months. Twenty-one (87.5%) patients completed 24 months of follow-up.
Sixteen (66.7%) patients had active uveitis at the beginning of therapy. One patient out
of these active patients had active inflammation at the end of follow-up period. Thirteen
(87.5%) out of sixteen active patients were in steroid-free remission. Themean duration of
treatment to induce remission was 16.5 months (range 6–24 months). Corticosteroid was
stopped in 19 (90.5%) patients by the end of the study. At the end of the study, in patients
who achieved remission, 14 (58.3%) patients were in remission on infliximab therapy and
6 (25%) patients were in remission off infliximab therapy. Of the 38 eyes, 8 (21.05%)
showed improvement in BCVA (three eyes had successful cataract extraction with
intraocular lens implantation during infliximab therapywith no subsequent inflammation),
while 26 eyes (68.4%) had stable BCVA over the 24-month study period. The side effects
included allergic reaction, fatigue, cellulitis, headache, restlessness, elevation of liver
enzymes, and anemia. Two patients (n = 24, 8.3%) experienced severe adverse effects
and the treatment was stopped prematurely in these two patients.
Conclusion: Infliximab might induce and maintain the steroid-free remission in HLA-
B27-associated ocular inflammation in patients resistant or intolerant to conventional
immunomodulatory therapy.
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INTRODUCTION
Acute anterior uveitis (AAU) is the most common
form of intraocular inflammatory disease and can
be associated with the human leukocyte antigen
(HLA)-B27 haplotype in approximately 55–71% of
patients.[1, 2] It usually manifests at a young age as
recurrent, acute, non-granulomatous uveitis, with
a unilateral or alternating bilateral presentation.
The disease may involve posterior segment in
the form of optic disc edema, macular edema,
choroidal folds and effusions, exudative retinal
detachment, and anterior and posterior scleritis.[3]
Intense inflammation and protein coagulum in the
aqueous may lead to temporary or permanent
severe visual impairment.
Topical corticosteroids, the first line of therapy,
are sometimes insufficient to control the intraocular
inflammation. Additional periocular and/or
systemic corticosteroids and sometimes both are
required to control the inflammation in more severe
cases. Corticosteroid treatment increases the risk
of systemic and ocular complications such as
glaucoma and cataract. Therefore, corticosteroid-
sparing conventional immunomodulatory
therapies such as methotrexate, azathioprine,
and mycophenolate mofetil (MMF) have been
employed in the treatment of these patients.
Biologic response modifier agents are the next
step of the step ladder approach in the treatment
of patients intolerant or resistant to conventional
immunomodulatory therapy (IMT).[4, 5]
Infliximab is a mouse–human chimeric
immunoglobulin G1 (IgG1) monoclonal antibody that
binds both the soluble and the membrane-bound
precursor of tumor necrosis factor-alpha (TNF-α)
and acts as a TNF-α inhibitor. It has been employed
off-label in the treatment of non-infectious ocular
inflammatory diseases refractory to conventional
IMT with a high rate of inflammation control and
few adverse effects.[6–14]
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There are very few studies which have
specifically focused on the HLA B-27-associated
ocular inflammation.[12, 13] Even fewer studies have
evaluated the efficacy and safety of infliximab
therapy in patients with HLA-B27-associated ocular
inflammation resistant or intolerant to conventional
IMT.[13] In this study, the efficacy and safety of
steroid-free infliximab therapy were assessed in an
HLA-B27 positive ocular inflammatory diseases in
patients resistant or intolerant to conventional IMT.
METHODS
This study was a single-center retrospective
observational case series. Approval for this
study was obtained through the New England
Institutional Review Board, which issued a waiver
of informed consent, as this was a retrospective
chart review analysis. This study was performed in
accordance with the Declaration of Helsinki and
was HIPAA compliant.
Electronic charts of patients with HLA-B27-
associated ocular inflammation and infliximab
(Remicade; Centocor, Inc, Malvern, Pennsylvania)
therapy between July 2005 and October 2012
were examined. Those patients who received
infliximab as the primary treatment were excluded.
Twenty-four patients (38 eyes) who had received
at least one conventional IMT and/or another
biologic response modifier agent were included in
the study. The baseline demographic data, clinical
diagnosis, and previous treatments were extracted
from the charts. The best-corrected visual acuity
(BCVA), slit lamp biomicroscopy, funduscopy
positive findings, and intraocular pressure prior
to and at 3, 6, 9, 12, 18, 24 months after starting
the infliximab therapy were collected. Flare-ups,
dose, and frequency of infliximab infusions,
duration of follow-up, and severe adverse effects
of infliximab were noted. Severe adverse effects
were described as a severe side effect significant
enough for the termination of infliximab therapy.
This is an open access journal, and articles are distributed under the terms of
the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which
allows others to remix, tweak, and build upon the work non-commercially, as
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Standardization of Uveitis Nomenclature (SUN)
Working Group grading scheme was used for
the assessment of anterior chamber cell and
flare.[15] Cases seen prior to the publication of
SUN guidelines were reclassified following the
new anatomical classification system. Inactive
anterior uveitis was defined as less than one plus
cells in anterior chamber and inactive vitreous
inflammation was defined as less than one plus
vitreous haze.[15, 16] Inactive scleritis was defined
based on Sen et al’s study.[17]
In this study, refractory ocular inflammation
was described as unresponsive inflammation
or intolerance to a three-month course of
treatment with at least two different conventional
immunomodulatory agents.
Patients without inflammation for the
consecutive six months of infliximab therapy
were categorized as ”remission on treatment”
group. The ”remission off treatment” group was
defined as inflammation-free for a period of six
consecutive months without infliximab treatment.
All patients had blood tests, which included a
complete blood cell count (CBC), liver function
tests (LFTs), and renal function tests before each
infusion. They also had purified protein derivative
skin test or QuantiFERON blood test, and anti-
nuclear antibody (ANA) once at baseline and yearly
afterward.
All patients received a loading dose of 5 mg/kg
at 0 and 2 weeks, then every 4 weeks for five
more infusions. However, some patients received
higher doses of infliximab such as 7.5 mg/kg then
10 mg/kg after the third infusion because of the
presence of inflammation in the complete ocular
examination and/or ancillary tests. After six months,
the frequency of infusions was stretched gradually
from 6 to 12 weeks based on the response to
the treatment and the absence of the active
inflammation. The treatment was stopped once
the patient was stable at the 12-week infliximab
infusion intervals for four consecutive infusions.
In this study, the side effects were defined
as adverse effects severe enough to justify
the treatment termination. All patients responded
to a questionnaire and the blood sample was
collected to evaluate for possible medication
toxicity in white blood cell (WBC), red blood
cell (RBC), platelet (PLT), alanine aminotransferase
(ALT), aspartate aminotransferase (AST), alkaline
phosphatase (ALKP), gamma glutamine transferase
(GGT), blood urea nitrogen (BUN), and creatinine
(Cr) before each infusion.
The primary outcome of the study was to
determine the efficacy of infliximab determined by
the control of inflammation, duration of remission,
and the ability to reduce conventional IMT. The
safety of the study was defined as the absence of
severe side effects. The secondary outcome was
an improvement of two or more lines of BCVA on
the Snellen acuity chart.
Statistical Analysis
Data were presented as descriptive statistics
(mean, percentages, range). Microsoft Excel 2010
(Microsoft, Richmond, VA) was used for statistical
analysis. Paired and unpaired two-tailed t-tests
were used to compare the number of medications,
intraocular pressure, and visual acuity changes
before and after the treatment. The level of
significance was set at P ≤ 0.05.
RESULTS
Twenty-four patients (38 eyes) were included in
the study. The average age of the patients was
44.7 ± 13.6 (12–67 years). Of the 24 patients, 14
(58.3%) were women and 14 (58.3%) had bilateral
involvement. The prevalence of one or more
associated systemic illness including ankylosing
spondylitis, reactive arthritis, inflammatory bowel
disease, psoriatic arthritis, and juvenile rheumatoid
arthritis was 70.8% (17 of 24) (Table 1). Sixteen
patients (n = 24, 66.7%) at baseline had active
ocular inflammation, which was reduced to only
one patient (n = 21, 4.7%) at the 24-month follow-
up visit (Table 2). Of the sixteen patients with active
ocular inflammation at baseline, 6 patients (37.5%)
and 10 eyes (38.5%) had chronic inflammation,
while the other 10 patients (62.5%) and 16 eyes
(61.5%) were diagnosed with an acute flare up. All
patients were on at least one conventional IMT
and/or another biologic response modifier agent
(Table 3).
The infliximab therapy was prematurely stopped
in three patients (12.5%) between the three- and
six months follow-up period due to one patient
with a severe allergic reaction (itching, rash, and
shortness of breath during the infusion), one
patient with a significant rise in liver enzymes (ALT
and ASTmore than 10 times of the normal), and one
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Table 1. General characteristics and medication
Characteristics Value
Age – yr
Mean ± SD 44.7 ± 13.6
Range 12–67
Female – no. (%) 14 (58.3)
Systemic Diseases† – no. (%) 17 (70.8)
AS 9 (37.5)
AS and RA 2 (8.3)




Conventional therapy Before infliximab patients (n = 24) (%) After infliximab patients (n = 24) (%)
Corticosteroids (by route)
None 0 (0) 19 (79.1)
Topical 21 (87.5) 4 (16)
Periocular and/or intraocular¶ 8 (33.3) –
Oral and/or intravenous 13 (38.1) 3 (12.5)
IMT (by number of medications)‡
None 0 (0) 7 (29.1)
1 medication 7 (29.2) 14 (58.3)
2 medications 8 (33.3) 2 (8.3)
≥3 medications 9 (37.5) 1 (4.1)
Side effects after infliximab (n = 24) 12 (50)
Allergic reaction – 2 (8.3)
Fatigue – 3 (12.5)
Cellulitis – 2 (8.3)
Headache, restlessness – 1 (4.2)
AST/ALT elevation – 2 (8.3)
Anemia – 2 (8.3)
†AS, ankylosing spondylitis; RA, reactive arthritis; IBD, inflammatory bowel disease; PA, psoriatic arthritis; NSA, nonspecific
arthritis; JIA, juvenile inflammatory arthritis
¶ At least one month before infliximab therapy
‡IMT, Immunomodulatory therapy
AST, aspartate aminotransferase; ALT, alanine aminotransferase
patient with insurance coverage problems (Figure
1).
Of the eight inactive patients (33.3%) at
baseline, six patients (25%) were started on
infliximab treatment due to intolerance to previous
conventional IMT therapy. In the other two patients
(8.3%), infliximab was started for an active systemic
disease by their rheumatologist. The latter two
developed an ocular inflammation during the first
three months of follow-up.
For the patients with active disease at baseline,
the duration of the treatment required to induce
remission varied from less than six months in
four (n = 16, 25%) patients to more than one
year in five (n = 16, 31.3%) patients. Six patients
(n =16, 37.5%) were in remission by the second
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Table 2. Inflammation status before and after the infliximab therapy excluding inactive patients
Ocular inflammation Before Infliximab
[patients (%)]
(n =16)
After Infliximab [patients (%)] (n = 16)
3 months 6 months 12 months 18 months 24 months
Active 16 (100) 3 (16.6) 2 (12.5) 2 (12.5) 2 (12.5) 1 (6.25)
Anterior uveitis 11 (68.7) 1 (6.25) – – 1 (6.25) –
Scleritis 2 (12.5) – – – – –
Vitritis 1 (6.25) – – – – –
Retinal vasculitis – 1 (6.25) 1 (6.25) 1 (6.25) 1 (6.25) 1 (6.25)
Anterior uveitis with retinal vasculitis – – 1 (6.25) – – –
Vitritis with retinal vasculitis 1 (6.25) – – 1 (6.25) – –
Papillitis with retinal vasculitis – 1 (6.25) – – – –
Vitritis, papillitis, and retinal vasculitis 1 (6.25) – – – – –
Table 3. Immunomulatory therapy before starting the infliximab therapy in patients with HLA-B27 ocular inflammation
Immunomodulatory therapy Number (%)
Methotrexate 10 (41.6%)









year of the follow-up period. At the end of the
study, 14 (58.3%) patients were in remission on
infliximab therapy and six (25%) were in remission
off infliximab therapy (Figure 2). The mean duration
between starting the treatment and induction of
remission was 16.5 months (range, 3–24 months).
Table 4 demonstrates how patients with flare up
were treated during the study period.
Before employing infliximab therapy, all patients
had received one or more routes of corticosteroid
administration, including topical, periocular,
systemic therapy based on the severity of
the disease. Twenty-one patients (87.5%) were
receiving topical corticosteroids; six patients
(37.5%), two patients (8.33%), and another two
patients (8.33%) received transseptal, intravenous,
and intravitreal corticosteroids, respectively.
Eleven patients (45.8%) were on oral prednisone;
higher doses (30–60 mg) were employed in four
patients (16.7%) with severe active inflammation.
Seven patients (29.1%) were on maintenance oral
prednisone therapy with an average dose of
8.7 mg (range, 7–10). Nineteen patients (90.5%)
discontinued corticosteroids by the end of the
study. At the 24-month follow-up, 13 patients
(87.5%) out of the 16 active patients were in
steroid-free remission. During the 24 months of
follow-up, the number of conventional IMT agents
were reduced in 14 (58.3%) patients, the dosage
of medications was halved in two patients (8.3%),
and medications were discontinued in five (n = 21,
23.8%) patients (Table 1). The average number of
medications before starting treatment was 2.3 ±
1.14 and at the end of the follow-up period was
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Table 4. Management of patients with ocular inflammation flare-up during the study period
Study period Number of patients with flare-up of
ocular inflammation
Treatment for flare-up
3-6 months 4 (17.4%, n = 23) 3 patients ( n = 23, 13%) – reducing the infliximab infusion interval
1 patient ( n = 23, 4.3%) – boosting infliximab dose
1 patient ( n = 23, 4.3%) with persistent vasculitis – MMF and CSA were
substituted for methotrexate and adalimumab
6–12 months 4 (19%, n = 21) 1 patient ( n = 21, 4.8%) with papillitis, vitritis, and retinal vasculitis –
received additional intravenous pulse steroids and was switched to
cyclophosphamide
2 patients ( n = 21, 9.5%) – received increased dose of infliximab
1 patient ( n = 21, 4.8%) with retinal vasculitis – received increased
doses of infliximab along with MMF and CSA
12–18 months 2 (9.5%, n = 21) 1 patient ( n = 21, 4.8%) with persistent retinal vasculitis – received
increased dose of infliximab along with oral corticosteroids
1 patients ( n = 21, 4.8%) – relapsed with anterior uveitis and was
restarted on infliximab
18–24 months 3 (14.3%, n = 21) 1 patient ( n = 21, 4.8%) – added methotrexate
1 patient ( n = 21, 4.8%) – reducing interval and boosting dose of
infliximab
1 patient ( n = 21, 4.8%) – increasing the dose of infliximab with oral
steroids
MMF, mycophenolate mofetil; CSA, Cyclosporin-A
Figure 1. The number of patients in total, with active and inactive disease at each follow-up visits.
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Figure 2. The number of patients with active disease, remission on infliximab Infliximab, remission off infliximab therapy before
starting the treatment and at the end of the follow-up period.
0.08 ± 0.2. The difference in the average number
of medications before starting the treatment and
at the end of the study period was statistically
significant (P < 0.0001).
Of the 38 eyes, 8 eyes (21.05%) showed
improvement in BCVA (three eyes had cataract
extraction with intraocular lens implantation
during infliximab therapy with no subsequent eye
inflammation), while 26 eyes (68.4%) had stable
BCVA over the 24-month study period. The mean
visual acuity before starting infliximab treatment
was 20/30–20/40 (0.22 ± 0.43LogMAR) and was
20/25 (0.1 ± 0.24LogMAR) after the treatment. The
mean difference of visual acuity before starting
infliximab therapy and at the end of 24 months of
follow-up was not statistically significant (P = 0.14).
Moreover, the changes in visual acuity in each
eye before starting the treatment and at the last
follow-up visit were not statistically significant (P =
0.06).
The average intraocular pressure in all uveitic
eyes of patients before starting infliximab therapy
was 16.3 ± 4.56 mmHg (10–34). The averages
of intraocular pressure in the worse and better
eyes of patients were 18.2 ± 4.61 mmHg and 14.5
± 3.44 mmHg, respectively. At the last follow-
up visit, the average of intraocular pressure in all
uveitic eyes of patients was 14.9 ± 2.00 mmHg
(10–20). Averages of intraocular pressure in the
worse eyes and better eyes of patients were
14.9 ± 2.07 and 14.57 ± 2.2 mmHg, respectively.
Using the paired t-test, the difference between
the intraocular pressure of the worse eye of each
patient before starting the treatment and at the last
follow-up was statistically significant (P = 0.004);
however, this difference was not significant in
the better involved eyes of each patient (P =
0.8).
The primary dose of infliximabwas 5mg/kg body
in 19 patients. In three patients (12.5%), infliximab
was started at the highest dose of 10 mg/kg: one
patient was monocular, one had severe scleritis,
and one had extensive retinal vasculitis.
The side effects included allergic reaction,
fatigue, cellulitis, headache, restlessness, elevation
of liver enzymes, and anemia. The treatment
was discontinued in three (12.5%) patients;
two due to the development of side effects
and one due to insurance problems. These
three patients were considered as treatment
failures.
DISCUSSION
The association between HLA-B27 positivity
and AAU with or without a spectrum of other
inflammatory diseases was originally described in
1973 and is one of the strongest HLA-disease
associations.[18, 19] TNF-α gene controls the
production of TNF-α, which is a cytokine
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and inflammatory mediator in animal models
of uveitis. TNF-α has been detected in the
uvea and retina at the early stages of acute
uveitis. In addition, TNF-α has been found
in higher levels in the sera and aqueous
humor of patients with uveitis.[5, 20] It may
induce expression of chemokines, adhesion
molecules, and other proinflammatory cytokines
causing protracted inflammatory process.[21]
Its blockade is associated with decreased
ocular inflammation in animal models.[22–24]
Sahrawi et al proposed that HLA B27-positive
individuals show a higher susceptibility toward
development of intraocular inflammation in
the presence of an A allele at nucleotide-238
and, to a lesser degree, at nucleotide-308 of
the TNF-α gene promoter.[25] These findings
formed the rationale for using the TNF-α inhibitor
biologic agents in HLA-B27-associated ocular
inflammatory diseases. Infliximab and adalimumab
are the most common TNF-α inhibitor biologic
response modifier agents employed in the
field of ophthalmology. The successful use of
infliximab and adalimumab for controlling ocular
and systemic inflammatory conditions has been
reported in different studies.[26–31] Adalimumab is
the only FDA-approved biologic for the treatment
of noninfectious uveitis.[29–31]
The median age (44 years) of our study sample
and the prevalence of associated systemic
illness (70%) matched earlier studies.[27–31]
Infliximab was well-tolerated and BCVA was
improved or remained stable in the majority
of our patients. Previous studies reported the
success of infliximab therapy in different ocular
inflammatory diseases with various etiologies
including HLA-B27-associated uveitis.[29–32] In
two studies by Foeldvari et al and Suhler et al,
the success of infliximab in JIA-associated uveitis
and panuveitis, intermediate uveitis and posterior
uveitis was 70% and 78%, respectively.[28, 31]
Kim et al and El-shabrawi et al found that
infliximab (3–5 mg/Kg body weight) was
effective in 76.2% and 66.7% of patients with
HLA-B27 anterior uveitis.[33, 34] In our study,
ocular inflammation was controlled in 83.3% of
patients at the end of two years; higher than
that reported in previous studies.[29, 32–34] This
can be attributed to adjustment of infliximab
dose up to 10 mg/kg based on the response to
infliximab therapy.[28, 31–33] While previous studies
used pulse or oral corticosteroid therapies to
control acute inflammation, the aim of our study
was to achieve steroid-free remission. Thus, a
significant number of our patients were not on
steroids for their ocular inflammation at the 24-
month follow-up visit. This can be interpreted
by the higher doses of infliximab and longer
duration of treatment that we employed in our
patients.[14, 35]
The starting dose for Infliximab therapy was
5 mg/kg in all patients except those with more
severe involvement such as retinal vasculitis
and scleritis. We followed the protocol of two
loading doses and five infusions every four weeks
before stretching the infusions. Slow tapering of
the infusions has been proved as an effective
way to maintain remission in patients on anti-
TNF-α inhibitor therapy.[34, 36–39] This was also
demonstrated in our study. Some of our patients
needed to increase the dose of infliximab, which
may be due to three possible hypotheses. The
first hypothesis is the development of an antibody
against the infliximab molecule due to its murine
constituent. This may be prevented by adding a
low-dose anti-metabolite to the regimen; however,
we were unable to make this conclusion due to low
sample size. A second possible reason to increase
the dose of infliximab is tachyphylaxis to the
medication itself. The third mechanism is the lower
dose of medication per age in younger individuals
due to their growth spurt and an increase in their
weight.
In this study, there were two patients with HLA-
B27 associated active systemic inflammation and
quiet eyes who were started on infliximab by the
rheumatologists and their intraocular inflammation
occurred early in the course of infliximab therapy.
There are two explanations for this finding. First,
it might be the natural course of the HLA-B27-
associated anterior uveitis, which was not under
control with the previous regimen and the time
for infliximab to control the inflammation was not
sufficient. Second, in our experience, there are
some patients with HLA-B27-associated ocular
inflammation who need higher doses of infliximab
for controlling ocular inflammation. In these
patients, ocular inflammation can recur despite
their systemic symptoms being controlled with
a standard dose of infliximab. That is why the
dose adjustment for ocular inflammation control
might be necessary after the third infliximab
infusion.
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Our study had the inherent limitations of a
retrospective study design with a small sample
size. As a tertiary care clinic, a large proportion
of our patients present with severe, long-standing,
and often unresponsive disease. Moreover, due
to the nature of our referral center which has
more severe and complicated cases, the trend
is toward a more aggressive therapy such as
infliximab rather than a less aggressive treatment
such as adalimumab injection, and this can also be
a source of selection bias. Furthermore, similar to
other retrospective studies, the inability to control
for confounding factors such as changes in topical,
local, and systemic corticosteroids and IMTs for
eye and systemic conditions may allow for the
development of uveitis early in the course of
infliximab therapy.
In summary, Infliximab therapy might be
an effective and safe method of treatment
for inducing and sustaining the steroid-free
remission in patients with HLA-B27-associated
ocular inflammation, which can be a serious and
potentially blinding condition if left untreated or
incompletely treated. However, to validate these
findings, more potent studies are required.
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